Skip to main content
Fig. 2 | Cell & Bioscience

Fig. 2

From: Liver-specific in vivo base editing of Angptl3 via AAV delivery efficiently lowers blood lipid levels in mice

Fig. 2

In vivo performance of AAV9-hAAT-Anc/Angptl3 in mice. (A) Schematic showing AAV9-hAAT-Anc/Angptl3 N- and C-terminal halves design. (B) Measurements of the serum levels of ANGPTL3 protein. (C, D) Measurements of serum TG (C) and TC (D) in mice at 1–4 weeks after AAV9-hAAT-Anc/Angptl3 administration. The control (Ctrl) mice received no treatments. ns, not significant; **p < 0.01, ***p < 0.001 and ****p < 0.0001; one-way ANOVA with Turkey’s multiple comparisons test

Back to article page

Cell & Bioscience

ISSN: 2045-3701

Contact us